{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:15:41Z","timestamp":1791346541623,"version":"4.3.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-54292-0","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T17:39:30Z","timestamp":1732556370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["In vivo gene editing of T-cells in lymph nodes for enhanced cancer immunotherapy"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5968-1069","authenticated-orcid":false,"given":"Jin","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuxiao","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingdao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheuk Yin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0252-2737","authenticated-orcid":false,"given":"Zixun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9339-7267","authenticated-orcid":false,"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becki Yi","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0629-4161","authenticated-orcid":false,"given":"Peng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"54292_CR1","doi-asserted-by":"crossref","unstructured":"Wang, C. et al. In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy. Nat. Biomed. Eng. 1, 0011 (2017).","DOI":"10.1038\/s41551-016-0011"},{"key":"54292_CR2","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s41565-019-0512-0","volume":"14","author":"J Conniot","year":"2019","unstructured":"Conniot, J. et al. Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators. Nat. Nanotechnol. 14, 891\u2013901 (2019).","journal-title":"Nat. Nanotechnol."},{"key":"54292_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56\u201361 (2015).","journal-title":"Science"},{"key":"54292_CR4","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"54292_CR5","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"54292_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41568-022-00544-4","volume":"23","author":"A van Weverwijk","year":"2023","unstructured":"van Weverwijk, A. & de Visser, K. E. Mechanisms driving the immunoregulatory function of cancer cells. Nat. Rev. Cancer 23, 193\u2013215 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"54292_CR7","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"54292_CR8","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006\u20132017 (2015).","journal-title":"N. Engl. J. Med."},{"key":"54292_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"54292_CR10","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber, J. S., K\u00e4hler, K. C. & Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30, 2691\u20132697 (2012).","journal-title":"J. Clin. Oncol."},{"key":"54292_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros, C. et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat. Rev. Clin. Oncol. 13, 473\u2013486 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"54292_CR12","unstructured":"Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 (2020)."},{"key":"54292_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0001-8","volume":"6","author":"S Su","year":"2016","unstructured":"Su, S. et al. CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci. Rep. 6, 1\u201314 (2016).","journal-title":"Sci. Rep."},{"key":"54292_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian, S. L., Taube, J. M., Anders, R. A. & Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275\u2013287 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"54292_CR15","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41591-020-0840-5","volume":"26","author":"Y Lu","year":"2020","unstructured":"Lu, Y. et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat. Med. 26, 732\u2013740 (2020).","journal-title":"Nat. Med."},{"key":"54292_CR16","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.molmed.2020.06.001","volume":"26","author":"SF Lacey","year":"2020","unstructured":"Lacey, S. F. & Fraietta, J. A. First Trial of CRISPR-Edited T cells in Lung Cancer. Trends Mol. Med. 26, 713\u2013715 (2020).","journal-title":"Trends Mol. Med."},{"key":"54292_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp, L. J. et al. CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci. Rep. 7, 1\u201310 (2017).","journal-title":"Sci. Rep."},{"key":"54292_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","volume":"2","author":"L Labanieh","year":"2018","unstructured":"Labanieh, L., Majzner, R. G. & Mackall, C. L. Programming CAR-T cells to kill cancer. Nat. Biomed. Eng. 2, 377\u2013391 (2018).","journal-title":"Nat. Biomed. Eng."},{"key":"54292_CR19","doi-asserted-by":"publisher","first-page":"eabn8264","DOI":"10.1126\/sciadv.abn8264","volume":"8","author":"AK Grosskopf","year":"2022","unstructured":"Grosskopf, A. K. et al. Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors. Sci. Adv. 8, eabn8264 (2022).","journal-title":"Sci. Adv."},{"key":"54292_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1115178","volume":"5","author":"U Koehl","year":"2016","unstructured":"Koehl, U. et al. Advances in clinical NK cell studies: donor selection, manufacturing and quality control. Oncoimmunology 5, e1115178 (2016).","journal-title":"Oncoimmunology"},{"key":"54292_CR21","doi-asserted-by":"crossref","unstructured":"Elsallab, M. & Maus, M. V. Expanding access to CAR T cell therapies through local manufacturing. Nat. Biotechnol. 41, 1698\u20131708 (2023).","DOI":"10.1038\/s41587-023-01981-8"},{"key":"54292_CR22","doi-asserted-by":"crossref","unstructured":"Kranjc, M. & Miklav\u010di\u010d, D. Electric field distribution and electroporation threshold. Handbook of Electroporation, 2, 1043\u20131058 (2016).","DOI":"10.1007\/978-3-319-32886-7_4"},{"key":"54292_CR23","doi-asserted-by":"publisher","first-page":"2100978","DOI":"10.1002\/advs.202100978","volume":"8","author":"EP Jenkins","year":"2021","unstructured":"Jenkins, E. P. et al. Electrotherapies for glioblastoma. Adv. Sci. 8, 2100978 (2021).","journal-title":"Adv. Sci."},{"key":"54292_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe, A. H. & Pauken, K. E. The diverse functions of the PD1 inhibitory pathway. Nat. Rev. Immunol. 18, 153\u2013167 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"54292_CR25","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41551-021-00720-1","volume":"5","author":"H Chang","year":"2021","unstructured":"Chang, H. et al. Cryomicroneedles for transdermal cell delivery. Nat. Biomed. Eng. 5, 1008\u20131018 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"54292_CR26","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1016\/j.drudis.2021.06.008","volume":"26","author":"D Eus\u00e9bio","year":"2021","unstructured":"Eus\u00e9bio, D. et al. Methods to improve the immunogenicity of plasmid DNA vaccines. Drug Discov. Today 26, 2575\u20132592 (2021).","journal-title":"Drug Discov. Today"},{"key":"54292_CR27","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.1016\/j.vaccine.2005.08.027","volume":"24","author":"P Bergman","year":"2006","unstructured":"Bergman, P. et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 24, 4582\u20134585 (2006).","journal-title":"Vaccine"},{"key":"54292_CR28","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/cid\/cir334","volume":"53","author":"B Ferraro","year":"2011","unstructured":"Ferraro, B. et al. Clinical applications of DNA vaccines: current progress. Clin. Infect. Dis. 53, 296\u2013302 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"54292_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1086\/515613","volume":"178","author":"RR MacGregor","year":"1998","unstructured":"MacGregor, R. R. et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J. Infect. Dis. 178, 92\u2013100 (1998).","journal-title":"J. Infect. Dis."},{"key":"54292_CR30","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/s41565-020-00781-4","volume":"15","author":"J Xu","year":"2020","unstructured":"Xu, J. et al. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy. Nat. Nanotechnol. 15, 1043\u20131052 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"54292_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fimmu.2012.00023","volume":"3","author":"BJ Baaten","year":"2012","unstructured":"Baaten, B. J., Tinoco, R., Chen, A. T. & Bradley, L. M. Regulation of antigen-experienced T cells: lessons from the quintessential memory marker CD44. Front. Immunol. 3, 23 (2012).","journal-title":"Front. Immunol."},{"key":"54292_CR32","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373\u2013377 (2015).","journal-title":"Nature"},{"key":"54292_CR33","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486\u2013499 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"54292_CR34","first-page":"97","volume":"33","author":"SB Stephan","year":"2015","unstructured":"Stephan, S. B. et al. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat. Nanotechnol. 33, 97\u2013101 (2015).","journal-title":"Nat. Nanotechnol."},{"key":"54292_CR35","doi-asserted-by":"publisher","first-page":"eabb4639","DOI":"10.1126\/sciadv.abb4639","volume":"6","author":"Q Fan","year":"2020","unstructured":"Fan, Q. et al. An implantable blood clot\u2013based immune niche for enhanced cancer vaccination. Sci. Adv. 6, eabb4639 (2020).","journal-title":"Sci. Adv."},{"key":"54292_CR36","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nnano.2011.164","volume":"6","author":"PE Boukany","year":"2011","unstructured":"Boukany, P. E. et al. Nanochannel electroporation delivers precise amounts of biomolecules into living cells. Nat. Nanotechnol. 6, 747\u2013754 (2011).","journal-title":"Nat. Nanotechnol."},{"key":"54292_CR37","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/nnano.2017.134","volume":"12","author":"D Gallego-P\u00e9rez","year":"2017","unstructured":"Gallego-P\u00e9rez, D. et al. Topical tissue nano-transfection mediates non-viral stroma reprogramming and rescue. Nat. Nanotechnol. 12, 974\u2013979 (2017).","journal-title":"Nat. Nanotechnol."},{"key":"54292_CR38","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41928-021-00614-9","volume":"4","author":"SM Mirvakili","year":"2021","unstructured":"Mirvakili, S. M. & Langer, R. Wireless on-demand drug delivery. Nat. Electron. 4, 464\u2013477 (2021).","journal-title":"Nat. Electron."},{"key":"54292_CR39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2322264121","volume":"121","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Transdermal microarrayed electroporation for enhanced cancer immunotherapy based on DNA vaccination. Proc. Nat. Acad. Sci. USA 121, e2322264121 (2024).","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"54292_CR40","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1021\/acs.nanolett.1c02503","volume":"22","author":"MM Billingsley","year":"2021","unstructured":"Billingsley, M. M. et al. Orthogonal Design of Experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells. Nano Lett. 22, 533\u2013542 (2021).","journal-title":"Nano Lett."},{"key":"54292_CR41","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.7150\/thno.23438","volume":"8","author":"D Huang","year":"2018","unstructured":"Huang, D. et al. Efficient delivery of nucleic acid molecules into skin by combined use of microneedle roller and flexible interdigitated electroporation array. Theranostics 8, 2361\u20132376 (2018).","journal-title":"Theranostics"},{"key":"54292_CR42","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1089\/ten.teb.2010.0520","volume":"17","author":"CT McKee","year":"2011","unstructured":"McKee, C. T., Last, J. A., Russell, P. & Murphy, C. J. Indentation versus tensile measurements of Young\u2019s modulus for soft biological tissues. Tissue Eng. Part B Rev. 17, 155\u2013164 (2011).","journal-title":"Tissue Eng. Part B Rev."},{"key":"54292_CR43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41551-019-0508-y","volume":"4","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs. Nat. Biomed. Eng. 4, 499\u2013506 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"54292_CR44","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.matt.2020.08.029","volume":"3","author":"S Cheng","year":"2020","unstructured":"Cheng, S. et al. Electronic Blood Vessel. Matter 3, 1664\u20131684 (2020).","journal-title":"Matter"},{"key":"54292_CR45","doi-asserted-by":"publisher","first-page":"045001","DOI":"10.1063\/10.0005649","volume":"4","author":"Z Dong","year":"2021","unstructured":"Dong, Z. & Chang, L. Recent electroporation-based systems for intracellular molecule delivery. Nanotechnol. Precis. Eng. 4, 045001 (2021).","journal-title":"Nanotechnol. Precis. Eng."},{"key":"54292_CR46","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1126\/science.281.5373.96","volume":"281","author":"P Garside","year":"1998","unstructured":"Garside, P. et al. Visualization of specific B and T lymphocyte interactions in the lymph node. Science 281, 96\u201399 (1998).","journal-title":"Science"},{"key":"54292_CR47","doi-asserted-by":"crossref","unstructured":"De Castro, V., Galaine, J., Loyon, R. & Godet, Y. CRISPR-Cas gene knockouts to optimize engineered T cells for cancer immunotherapy. Cancer Gene Ther. 31, 1124\u20131134 (2024).","DOI":"10.1038\/s41417-024-00771-x"},{"key":"54292_CR48","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nri3790","volume":"15","author":"LT Nguyen","year":"2015","unstructured":"Nguyen, L. T. & Ohashi, P. S. Clinical blockade of PD1 and LAG3\u2013potential mechanisms of action. Nat. Rev. Immunol. 15, 45\u201356 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"54292_CR49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/intimm\/dxs098","volume":"25","author":"M-L Thibult","year":"2013","unstructured":"Thibult, M.-L. et al. PD-1 is a novel regulator of human B-cell activation. Int. Immunol. 25, 129\u2013137 (2013)","journal-title":"Int. Immunol."},{"key":"54292_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-19486-2","volume":"11","author":"N Parayath","year":"2020","unstructured":"Parayath, N., Stephan, S., Koehne, A., Nelson, P. & Stephan, M. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat. Commun. 11, 1\u201317 (2020).","journal-title":"Nat. Commun."},{"key":"54292_CR51","doi-asserted-by":"crossref","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u221296 (2022).","DOI":"10.1126\/science.abm0594"},{"key":"54292_CR52","doi-asserted-by":"crossref","unstructured":"Mardiana, S., Solomon, B. J., Darcy, P. K. & Beavis, P. A. Supercharging adoptive T cell therapy to overcome solid tumor\u2013induced immunosuppression. Sci. Transl. Med. 11, eaaw2293 (2019).","DOI":"10.1126\/scitranslmed.aaw2293"},{"key":"54292_CR53","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.3389\/fonc.2020.01726","volume":"10","author":"R Rosell","year":"2020","unstructured":"Rosell, R., Filipska, M., Chaib, I., Llige, D. & Laguia, F. Commentary: safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Front. Oncol. 10, 1726 (2020).","journal-title":"Front. Oncol."},{"key":"54292_CR54","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1021\/acs.nanolett.5b05030","volume":"16","author":"C Wang","year":"2016","unstructured":"Wang, C., Ye, Y., Hochu, G. M., Sadeghifar, H. & Gu, Z. Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody. Nano Lett. 16, 2334\u20132340 (2016).","journal-title":"Nano Lett."},{"key":"54292_CR55","doi-asserted-by":"publisher","first-page":"40085","DOI":"10.1021\/acsami.0c11156","volume":"12","author":"Q Shang","year":"2020","unstructured":"Shang, Q. et al. Rational design of a robust antibody-like small-molecule inhibitor nanoplatform for enhanced photoimmunotherapy. Acs Appl. Mater. Inter. 12, 40085\u201340093 (2020).","journal-title":"Acs Appl. Mater. Inter."},{"key":"54292_CR56","doi-asserted-by":"crossref","unstructured":"Bois, H. D., Heim, T. A. & Lund, A. W. Tumor-draining lymph nodes: at the crossroads of metastasis and immunity. Sci. Immunol. 6, eabg3551 (2021).","DOI":"10.1126\/sciimmunol.abg3551"},{"key":"54292_CR57","doi-asserted-by":"crossref","unstructured":"Francis, D. M. et al. Blockade of immune checkpoints in lymphnodes through locoregional delivery augmentscancer immunotherapy. Sci. Transl. Med. 12, eaay3575 (2020).","DOI":"10.1126\/scitranslmed.aay3575"},{"key":"54292_CR58","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"54292_CR59","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nbt.3290","volume":"33","author":"A Hendel","year":"2015","unstructured":"Hendel, A. et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat. Biotechnol. 33, 985\u2013989 (2015).","journal-title":"Nat. Biotechnol."},{"key":"54292_CR60","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","volume":"23","author":"J Ren","year":"2017","unstructured":"Ren, J. et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin. Cancer Res. 23, 2255\u20132266 (2017).","journal-title":"Clin. Cancer Res."},{"key":"54292_CR61","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1101\/gr.171322.113","volume":"24","author":"S Kim","year":"2014","unstructured":"Kim, S., Kim, D., Cho, S. W., Kim, J. & Kim, J.-S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 24, 1012\u20131019 (2014).","journal-title":"Genome Res."},{"key":"54292_CR62","doi-asserted-by":"publisher","first-page":"9874","DOI":"10.1021\/acs.chemrev.6b00799","volume":"117","author":"HX Wang","year":"2017","unstructured":"Wang, H. X. et al. CRISPR\/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery. Chem. Rev. 117, 9874\u20139906 (2017).","journal-title":"Chem. Rev."},{"key":"54292_CR63","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.stem.2017.11.010","volume":"22","author":"K Miyamoto","year":"2018","unstructured":"Miyamoto, K. et al. Direct in vivo reprogramming with Sendai virus vectors improves cardiac function after myocardial infarction. Cell Stem Cell 22, 91\u2013103.e105 (2018).","journal-title":"Cell Stem Cell"},{"key":"54292_CR64","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41586-018-0477-4","volume":"561","author":"M Kurita","year":"2018","unstructured":"Kurita, M. et al. In vivo reprogramming of wound-resident cells generates skin epithelial tissue. Nature 561, 243\u2013247 (2018).","journal-title":"Nature"},{"key":"54292_CR65","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1016\/j.actbio.2014.02.035","volume":"10","author":"E Kaemmerer","year":"2014","unstructured":"Kaemmerer, E. et al. Gelatine methacrylamide-based hydrogels: an alternative three-dimensional cancer cell culture system. Acta Biomater. 10, 2551\u20132562 (2014).","journal-title":"Acta Biomater."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54292-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54292-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54292-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T19:02:35Z","timestamp":1732561355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54292-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["54292"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-54292-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"7 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: P.S., J.Q., Y.W., and X.H. are listed as inventors on a patent application, titled \u201cMicro-electroporation based drug delivery system, methods for use and fabrication thereof\u201d (US Priority No. 17\/804,118), filed by the City University of Hong Kong. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10218"}}